Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance.

English summary

This multicenter prospective study developed a population pharmacokinetic model to describe pyrazinamide (PZA) pharmacokinetics in Korean patients with tuberculosis and evaluated the effects of geriatric age and diabetes mellitus on PZA clearance.

Key points

• Random post-dose PZA concentrations, demographic characteristics, and clinical information were collected from 610 tuberculosis patients at 18 hospitals in Korea.
• The data were divided into training and test datasets at a 4:1 ratio, and the population pharmacokinetic model was developed using a nonlinear mixed-effects method.
• A one-compartment model with allometric scaling for body size adequately described PZA pharmacokinetics‌ .

Audience

Clinicians, clinical pharmacologists, tuberculosis researchers, and advanced learners interested in therapeutic drug monitoring and precision dose design

Scope and limitations

The study is based on Korean patients with tuberculosis and randomly timed post-dose concentration measurements. The reported findings concern the developed model and its evaluation with the external test dataset; the source text does not establish generalizability to other countries, patient populations, or sampling designs.

Research context

The study connects with themes in Sangzin Ahn’s portfolio involving population pharmacokinetic modeling, exposure prediction based on patient characteristics, and dose optimization within pharmacology and precision medicine.